MADISON, Wis.–(BUSINESS WIRE)–Recently published results from an evaluation of 1,065 chemical and drug substances using the devTOX quickPredict (devTOXqP) screening platform developed by Stemina Biomarker Discovery, Inc. demonstrated the platform’s ability to predict developmental toxicity in humans with high accuracy using a cell-based test. In a peer-reviewed article published in Toxicological Sciences, scientists from the U.S. Environmental Protection Agency (EPA) reported that Stemina’s devTOXqP test predicted the potential for developmental toxicity in a blinded set of chemicals and drugs from the agency’s ToxCast™ program with an accuracy of 82%, where there was clear evidence of toxicity in humans or in animal studies. The agency’s research suggests that devTOXqP is a useful tool for predicting developmental toxicants in humans and reducing the need for animal testing.
- Mobile app developed by a Madison startup shows promise in treating lower back pain and lowering health care costs
- The 250 Most Successful Companies in the Midwest
- SHINE Medical CEO Talks Europe Expansion, Future Phases of Company
- Stemina’s Human Stem Cell-Based Test Demonstrates Potential to Predict Which Drugs and Chemicals Cause Birth Defects
- Madison company’s surgery imaging device approved by FDA